Last reviewed · How we verify
Ferumoxytol intravenous — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Ferumoxytol intravenous (Ferumoxytol intravenous) — Auerbach Hematology Oncology Associates P C.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ferumoxytol intravenous TARGET | Ferumoxytol intravenous | Auerbach Hematology Oncology Associates P C | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ferumoxytol intravenous CI watch — RSS
- Ferumoxytol intravenous CI watch — Atom
- Ferumoxytol intravenous CI watch — JSON
- Ferumoxytol intravenous alone — RSS
Cite this brief
Drug Landscape (2026). Ferumoxytol intravenous — Competitive Intelligence Brief. https://druglandscape.com/ci/ferumoxytol-intravenous. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab